Scientists to Designs Nano-particles with Contrast Agents | Mammography
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Mammography Scientists to Designs Nano-particles with Contrast Agents

Scientists to Designs Nano-particles with Contrast Agents

Radiology News - Mammography

A pair of Toronto scientists has developed a unique technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms to improve early detection and treatment of cancer.

While contrast agents are routinely injected into patients to enhance the quality of medical images, different agents are currently required for various imaging modes (e.g. MRI , CT , PET ) each with inherent strengths and limitations. By combining more than one contrast agent into a nano-particle for use in multiple types of imaging, not only are physicians and researchers able to use lower doses of contrast agents (with lower toxicity) but the nano-particle also enables targeted delivery to, and retention by, specific tumours.

This nano-particle technology comes from the labs of two leading scientists in distinct yet complementary disciplines in the evolution of medical imaging - biophysics and pharmacy:

  • Dr. David Jaffray is a Senior Scientist in the Division of Biophysics and Bioimaging at the Ontario Cancer Institute, Head of the Radiation Physics Department at Princess Margaret Hospital and a Professor of Radiation Oncology and Medical Biophysics at the University of Toronto.
  • Dr. Christine Allen is an Associate Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto (currently on sabbatical at the STTARR Innovation Centre at University Health Network).

"Nano-particle technology enables us to route the contrast agent differently within the body - making it circulate longer and target disease processes for detection and characterization," Dr. Jaffray explained. "With the growing demand to characterize disease through imaging, this platform shows genuine promise."

MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology.

This collaborative commercialization deal - the third for MaRS Innovation in five months - is another step on the path to converting outstanding science into products and services that enhance Canada's economy and the quality of life for Canadians and others around the world.

Source: MaRS Innovation

Discuss more about Radiology in our Radiology group

 

Related Articles